中恒集团子公司以5500万元受让取得一种治疗慢性心力衰竭的药物技术

Core Viewpoint - Zhongheng Group's subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., has acquired a patent for a drug (LZ-01) that treats chronic heart failure, enhancing the company's product line and market competitiveness [1] Group 1: Acquisition Details - The acquisition price for the drug technology is 55 million yuan (excluding tax) [1] - The drug LZ-01 was initially discovered by the Navy Medical University of the People's Liberation Army and is noted for significantly improving myocardial energy metabolism and heart function in chronic heart failure patients [1] Group 2: Strategic Implications - The acquisition aligns with Zhongheng Group's strategic planning and is expected to expand the company's business and enhance its market competitiveness [1] - LZ-01 is characterized by good drug properties and oral administration, with no similar products available domestically or internationally, providing a significant therapeutic advantage for patients with reduced ejection fraction chronic heart failure [1]